XTX Topco Ltd Has $1 Million Holdings in 23andMe Holding Co. (NASDAQ:ME)

XTX Topco Ltd lifted its position in shares of 23andMe Holding Co. (NASDAQ:ME) by 36.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 439,468 shares of the company’s stock after purchasing an additional 118,534 shares during the quarter. XTX Topco Ltd owned approximately 0.10% of 23andMe worth $1,002,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Teacher Retirement System of Texas lifted its position in shares of 23andMe by 22.6% during the 2nd quarter. Teacher Retirement System of Texas now owns 23,321 shares of the company’s stock worth $58,000 after buying an additional 4,298 shares during the period. ProShare Advisors LLC raised its position in 23andMe by 26.1% in the 1st quarter. ProShare Advisors LLC now owns 21,854 shares of the company’s stock valued at $84,000 after purchasing an additional 4,525 shares during the last quarter. US Bancorp DE raised its position in 23andMe by 9.6% in the 1st quarter. US Bancorp DE now owns 59,416 shares of the company’s stock valued at $229,000 after purchasing an additional 5,188 shares during the last quarter. Principal Financial Group Inc. raised its position in 23andMe by 25.3% in the 1st quarter. Principal Financial Group Inc. now owns 28,756 shares of the company’s stock valued at $66,000 after purchasing an additional 5,810 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its position in 23andMe by 22.2% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 33,042 shares of the company’s stock valued at $75,000 after purchasing an additional 6,009 shares during the last quarter. Institutional investors and hedge funds own 28.23% of the company’s stock.

Insider Buying and Selling at 23andMe

In other 23andMe news, insider Kathy L. Hibbs sold 40,894 shares of the business’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $1.89, for a total value of $77,289.66. Following the completion of the transaction, the insider now directly owns 257,140 shares of the company’s stock, valued at $485,994.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 207,008 shares of company stock valued at $321,714. Company insiders own 27.55% of the company’s stock.

23andMe Stock Down 2.8 %

Shares of 23andMe stock opened at $1.05 on Friday. 23andMe Holding Co. has a 12 month low of $0.99 and a 12 month high of $3.68. The business has a fifty day simple moving average of $1.52 and a 200 day simple moving average of $1.91. The stock has a market cap of $496.11 million, a PE ratio of -1.49 and a beta of 1.42.

23andMe (NASDAQ:ME) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.22) EPS for the quarter. 23andMe had a negative return on equity of 43.59% and a negative net margin of 110.45%. The company had revenue of $60.86 million for the quarter, compared to analyst estimates of $56.90 million.

Analyst Ratings Changes

Separately, Citigroup lowered their target price on 23andMe from $2.50 to $1.75 and set a “buy” rating for the company in a research note on Thursday, August 10th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, 23andMe has an average rating of “Buy” and a consensus target price of $5.35.

23andMe Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.